Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 2/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21638825 | 0.89 | NR1H2 (0.32) | MAPTEHMT2KLKB1GLSDDB1 | |
| SCHEMBL21638846 | 0.80 | GLS (0.31) | GLS | |
| SCHEMBL18107012 | 0.78 | GLS (0.33) | GLSNAMPT | |
| SCHEMBL20110367 | 0.77 | MAPT (0.37) | MAPTEHMT2DDB1CRBNNAMPT | |
| SCHEMBL20102315 | 0.77 | — | — | |
| SCHEMBL18114792 | 0.75 | KRAS (0.34) | GLS | |
| SCHEMBL21638878 | 0.75 | DTYMK (0.39) | NAMPT | |
| SCHEMBL5225649 | 0.74 | POLB (0.38) | MAPTNAMPT | |
| SCHEMBL21638910 | 0.73 | KMT2A (0.42) | MAPTEHMT2NAMPT | |
| SCHEMBL5186966 | 0.73 | PREP (0.34) | MAPTNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118765-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118765-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | NQO1, PEPD, LCT | MAPT 3971/4885EHMT2 2992/4885KLKB1 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.